



1/18/05

CASE HL/95-22115/A/PCT/CONT

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dolores DeCarmino
Type or print name

Dolores DeCarmino
Signature

4/18/05
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Group Art Unit: 1621

PAUL ADRIAAN VAN DER SCHAAF ET AL

Examiner: S. A. Barts

APPLICATION NO: 10/736,195

Confirmation No. 4349

FILED: DECEMBER 15, 2003

FOR: POLYMORPHIC FORMS OF SERTRALINE

HYDROCHLORIDE

Mail Stop Petition

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

AMENDMENT, PETITION AND FEE DELETING CORRECTLY NAMED PERSON WHO
IS NOT AN INVENTOR OF THE INVENTION NOW BEING CLAIMED (37 CFR § 1.48(b))

Dear Sir:

This amendment and petition under 37 CFR § 1.48(b) is to **delete** the name of:

Regina Peter

as a named inventor on the grounds that she is not an inventor of the invention now being claimed.

While claims 1-9, all directed to a process to produce polymorphic form II of sertraline hydrochloride are pending in this continuation application, the parent application, application no. 10/111,947, contained 27 claims directed to multiple polymorphic forms of sertraline hydrochloride. Responsive to

a restriction requirement, claims directed to form II were elected, and the claims directed to the non-elected inventions were cancelled. Hence the invention of Regina Peter is no longer being claimed.

This amendment and petition under 37 CFR § 1.48(b) is being timely filed within 2 weeks of being advised of the need to correct inventorship.

The Commissioner is authorized to charge the fee required under 37 CFR § 1.17(i) in the amount of \$130.00 and any other fee or credit any overpayment due as a result of this Amendment/Petition under 37 CFR. § 1.48(b).

The Examiner is requested to contact the undersigned in the event any clarification or other information is necessary.


Respectfully submitted,



Kevin T. Mansfield
Agent for Applicants
Reg. No. 31,635

Ciba Specialty Chemicals Corporation
Patent Department
540 White Plains Road
P.O. Box 2005
Tarrytown, NY 10591-9005
(914) 785-7127
KTM22115CDellInv

APR 18 2005



CASE HL/95-22115/A/PCT/CONT

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dolores DeCarmino
Type or print name

Dolores DeCarmino
Signature

4/18/05
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Group Art Unit: 1621

PAUL ADRIAAN VAN DER SCHAAF ET AL

Examiner: S. A. Barts

APPLICATION NO: 10/736,195

Confirmation No. 4349

FILED: DECEMBER 15, 2003

FOR: POLYMORPHIC FORMS OF SERTRALINE
HYDROCHLORIDE

Mail Stop Petition

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**AMENDMENT, PETITION AND FEE DELETING CORRECTLY NAMED PERSON WHO
IS NOT AN INVENTOR OF THE INVENTION NOW BEING CLAIMED (37 CFR § 1.48(b))**

Dear Sir:

This amendment and petition under 37 CFR § 1.48(b) is to **delete** the name of:

Regina Peter

as a named inventor on the grounds that she is not an inventor of the invention now being claimed.

While claims 1-9, all directed to a process to produce polymorphic form II of sertraline hydrochloride are pending in this continuation application, the parent application, application no. 10/111,947, contained 27 claims directed to multiple polymorphic forms of sertraline hydrochloride. Responsive to

a restriction requirement, claims directed to form II were elected, and the claims directed to the non-elected inventions were cancelled. Hence the invention of Regina Peter is no longer being claimed.

This amendment and petition under 37 CFR § 1.48(b) is being timely filed within 2 weeks of being advised of the need to correct inventorship.

The Commissioner is authorized to charge the fee required under 37 CFR § 1.17(i) in the amount of \$130.00 and any other fee or credit any overpayment due as a result of this Amendment/Petition under 37 CFR. § 1.48(b).

The Examiner is requested to contact the undersigned in the event any clarification or other information is necessary.

Respectfully submitted,



Kevin T. Mansfield
Agent for Applicants
Reg. No. 31,635

Ciba Specialty Chemicals Corporation
Patent Department
540 White Plains Road
P.O. Box 2005
Tarrytown, NY 10591-9005
(914) 785-7127
KTM\22115CDelInv

APR 18 2005